US 11680090
Interleukin-2 fusion proteins and uses thereof
granted A61KA61K38/00A61K38/1761
Quick answer
US patent 11680090 (Interleukin-2 fusion proteins and uses thereof) held by Medicenna Therapeutics Inc. expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Medicenna Therapeutics Inc.
- Grant date
- Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K38/00, A61K38/1761, A61K38/2013, A61P